Cargando…

Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer’s patients in long-term care health facilities

BACKGROUND: Cholinesterase inhibitors can delay the progression of Alzheimer’s disease (AD). Several clinical trials of the drug in moderate to severe AD have consistently reported clinically positive effects. A combining effect with psychosocial intervention was reported in mild to moderate AD pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meguro, Kenichi, Ouchi, Yoshitaka, Akanuma, Kyoko, Meguro, Mitsue, Kasai, Mari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280048/ https://www.ncbi.nlm.nih.gov/pubmed/25516360 http://dx.doi.org/10.1186/s12883-014-0243-7

Ejemplares similares

Donepezil and life expectancy in Alzheimer’s disease: A retrospective analysis in the Tajiri Project
por: Meguro, Kenichi, et al.
Publicado: (2014)

Lifetime expectancy and quality-adjusted life-year in Alzheimer’s disease with and without cerebrovascular disease: effects of nursing home replacement and donepezil administration – a retrospective analysis in the Tajiri Project
por: Meguro, Kenichi, et al.
Publicado: (2015)

Normal Hearing Ability but Impaired Auditory Selective Attention Associated with Prediction of Response to Donepezil in Patients with Alzheimer's Disease
por: Ouchi, Yoshitaka, et al.
Publicado: (2015)

Patient-Reported Outcome Is Important in Psychosocial Intervention for Dementia: A Secondary Analysis of a Randomized Controlled Trial of Group Reminiscence Approach Data
por: Meguro, Kenichi, et al.
Publicado: (2013)

Qualitative Assessment of Instrumental Activities of Daily Living in Older Persons with Very Mild Dementia: The Kurihara Project
por: Ouchi, Yoshitaka, et al.
Publicado: (2016)

Estimated Quality-Adjusted Life-Year Associated with the Degree of Activities of Daily Living in Patients with Alzheimer's Disease
por: Kasai, Mari, et al.
Publicado: (2013)

Kanji and Kana agraphia in mild cognitive impairment and dementia: A trans-cultural comparison of elderly Japanese subjects living in Japan and Brazil
por: Akanuma, Kyoko, et al.
Publicado: (2010)

Semantic Dementia Shows both Storage and Access Disorders of Semantic Memory
por: Takahashi, Yumi, et al.
Publicado: (2014)

Decreased Behavioral Abnormalities After Treatment with Combined Donepezil and Yokukansankachimpihange in Alzheimer Disease: An Observational Study. The Osaki-Tajiri Project
por: Meguro, Kenichi, et al.
Publicado: (2018)

Collage technique may provide new perspectives for Alzheimer patients by exploring messages from their inner world
por: Meguro, Mitsue, et al.
Publicado: (2009)

Screening for Very Mild Subcortical Vascular Dementia Patients Aged 75 and Above Using the Montreal Cognitive Assessment and Mini-Mental State Examination in a Community: The Kurihara Project
por: Kasai, Mari, et al.
Publicado: (2012)

Alzheimer’s patients do not show left unilateral spatial neglect but exhibit peripheral inattention and simplification
por: Kasai, Mari, et al.
Publicado: (2007)

More Delusions May Be Observed in Low-Proficient Multilingual Alzheimer’s Disease Patients
por: Liu, Yi-Chien, et al.
Publicado: (2015)

Patients With Very Mild Dementia May Confuse Objective Cognitive Impairments With Subjective Physical Health of Quality of Life: The Tome City Project in Japan
por: Kasai, Mari, et al.
Publicado: (2018)

Impaired Shifting of Visuospatial Attention in Alzheimer’s disease as Shown by the Covert Orienting Paradigm: Implications for Visual Construction Disability
por: Ishizaki, Junichi, et al.
Publicado: (2013)

Word Processing Is Faster than Picture Processing in Alzheimer's Disease
por: Meguro, Kenichi, et al.
Publicado: (2020)

Impaired Eating and Swallowing Function in Older Adults in the Community: The Kurihara Project
por: Takahashi, Kyoko, et al.
Publicado: (2019)

Neuroepidemiologic and Neurobehavioral Characteristics of Motoric Cognitive Risk Syndrome in an Old-Old Population: The Kurihara Project
por: Kumai, Keiichi, et al.
Publicado: (2016)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Depression and Dementia in Old-Old Population: History of Depression May Be Associated with Dementia Onset. The Tome Project
por: Liu, Yi-Chien, et al.
Publicado: (2017)

Self-Reported Cognitive Decline Based on the Ascertain Dementia 8 Questionnaire May Be Effective for Detecting Mild Cognitive Impairment and Dementia in the Community: The Wakuya Project
por: Kasai, Mari, et al.
Publicado: (2021)

Decreased Physical Activity Associated with Executive Dysfunction Correlates with Cognitive Impairment among Older Adults in the Community: A Retrospective Analysis from the Kurihara Project
por: Kobayashi, Yoritoshi, et al.
Publicado: (2016)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Hardy, Chris J. D., et al.
Publicado: (2017)

Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Studies on Interaction of Buffalo Brain Cystatin with Donepezil: An Alzheimer's Drug
por: Amin, Fakhra, et al.
Publicado: (2013)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
por: Unzeta, Mercedes, et al.
Publicado: (2016)

Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease
por: Hwang, Yun Tae, et al.
Publicado: (2018)

Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Campbell, Tom A., et al.
Publicado: (2018)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fhnd0dnq46mm63maqor8v0o3te